KHRN

Khiron is well positioned to expand Zerenia™ clinics in Brazil following its successful introduction in July 2021 of Khiron-branded medical CBD. Dr. Eduardo Faveret, a thought leader and innovator in medical cannabis, has been appointed as Medical Director and will be leading the clinic. Dr. Faveret and the Zerenia™ Rio clinic will be sup... Read More...

Khiron's Medical Clinics and Distribution Growth Throughout Europe Follows Success in Latin American Marketplace Since establishing a Spanish subsidiary in 2019, Khiron's scientific and medical team is recognized as cannabinoid experts in Spain Khiron continues its long-standing relationship with the Spanish Agency of Medicines and Medic... Read More...

TORONTO, June 23, 2022 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Latin America and Europe, announces the results of its 2022 Annual General and Special Meeting of shareholders (the "Meeting") held on June 23, 2022. Shareholders approved all of th... Read More...

Continues market leadership in Colombia, Latin America's only country with universal health coverage for medical cannabis Market leader in the Colombian medical cannabis market, with Q1 2022 volume sales exceeding 21,400 units, up 280% YoY and more than 40% of all 2021 New clinic continues Khiron's unique patient acquisition and retentio... Read More...

Data Substantiates Company's Position as a Global Leader In Health Care Solutions Key findings in the study include: 9 out of 10 patients reported some degree of improvement of their chronic pain. 7 out of 10 reported an improvement larger than 50% after 4 weeks of treatment. 7 out of 10 patients did not experience any adverse effects re... Read More...

Teleton has 24 Medical Centers (22 rehabilitation centers, 1 autism center and 1 Children's Hospital for Cancer) located across the country, and around 600,000 patients with disability, cancer and autism conditions The partnership includes: Establishment of Khiron's Zerenia™ medical cannabis clinics within Teleton's network across Mexico... Read More...

TORONTO, March 7, 2022 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a medical cannabis leader with core operations in Latin America and Europe, is scheduled to participate in the following virtual and in-person conferences in March 2022: Q1 2022 VIRTUAL INVESTOR SUMMIT March 8 -10, 2022  Khiron Pr... Read More...

TORONTO, Nov. 8, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is scheduled to participate in the following virtual and in-person conferences in November 2021: CANNABIS EUROPABanking Hall, LondonNovember ... Read More...

Zerenia™ Clinics UK is a specialist medical cannabis clinic in London and another strategic approach by Khiron to improve access to medical cannabis for patients in the UK Hybrid clinic model: Zerenia™ Clinics UK is a digital clinic (www.zereniaclinic.co.uk) and will also offer in-person appointments with medical cannabis specialist pra... Read More...

TORONTO, Oct. 4, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated international cannabis leader with core operations in Latin America and Europe, is pleased to provide a corporate update on global medical cannabis operations: Medical Cannabis Latin America Medical cannab... Read More...

TORONTO, Oct. 1, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announced that Joel Friedman, has resigned as Chief Financial Officer of the Company for personal reasons. Khiron's board of d... Read More...

TORONTO, Sept. 13, 2021 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce that, further to its September 9, 2021 press release, the Company has received final approval from the TSX... Read More...

TORONTO, Sept. 9, 2021 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF) , (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces today its intention to renew its prior normal course issuer bid through the facilities of the TSX Venture Ex... Read More...

Currently in Peru, the Company sells magistral preparations, or customized compound formulations, through its exclusive agreement with Farmacia Universal. In contrast, as shelf-ready medical cannabis products, Alixen™ 30™ and Alixen™ 100 will be made widely available, on a non-exclusive basis in the country.  Alixen™ 30 will target indic... Read More...

"At Khiron, sustainability is embedded in our DNA, with the common belief that strong ESG policies improve performance, loyalty, and innovation, while reducing corporate risks and capital costs. Our inaugural ESG report demonstrates our dedication to strong environmental, social and governance principles as we deliver on our Mission of im... Read More...

In 2013, Dr. Faveret became one of the first Brazilian physicians to prescribe medical cannabis, subsequently treating more than 3,000 patients with various conditions across the country As Medical Director for Zerenia™, Dr. Faveret will lead patient prescriptions, physician outreach and education, and data-driven product development fo... Read More...

On July 23, 2021, the Colombian Government signed Decree 811 of 2021, expanding the regulatory framework for domestic and export medical cannabis markets in Colombia With the Decree, Colombia continues to serve as a regulatory leader and reference point for other countries in the region, having also approved universal insurance coverage... Read More...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, July 8, 2021 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has closed its offering to U.S. institutional investors of 27,435,000 units of the Company (the "Offered Units"),... Read More...